Related Experiment Video

Updated: Sep 13, 2025

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.1K

Disrupting Cell Cycle Machinery: CREPT Is an Emerging Target in Cancer Therapy

Umar Farooq1, Jun Li1, Zhijie Chang2

  • 1Jinfeng Laboratory, No. 313 Jinyue Road, High-Tech Zone, Chongqing 401329, China.

Cancers
|July 29, 2025
PubMed

Insights

Cell-cycle-related and expression-elevated protein in tumors (CREPT) drives cancer by activating key pathways. Targeting CREPT shows promise for reversing tumor growth and enhancing immunotherapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • Cell-cycle-related and expression-elevated protein in tumors (CREPT) is a transcriptional co-factor.
  • CREPT dysregulation drives tumorigenesis by activating oncogenic signaling pathways like Wnt/β-catenin, STAT3, and NF-κB/TNFR2.
  • Aberrant CREPT expression correlates with poor patient survival across various cancers.

Purpose of the Study:

  • To review the multifaceted roles of CREPT in cancer.
  • To explore CREPT's involvement in the hallmarks of cancer.
  • To propose CREPT as a therapeutic target for cancer treatment.

Main Methods:

  • Review of preclinical studies involving CREPT knockdown using shRNA.
  • Analysis of research on CREPT's functions in metabolic regulation, tissue repair, and microenvironmental remodeling.
  • Examination of current strategies targeting CREPT, including miRNA-based approaches.

Main Results:

  • CREPT knockdown demonstrated sustained tumor growth regression in preclinical models.
  • CREPT regulates multiple cancer-promoting signaling pathways.
  • Emerging evidence highlights CREPT's pleiotropic functions beyond cell cycle control.

Conclusions:

  • Targeting CREPT holds significant potential to reverse tumor progression.
  • Combining CREPT inhibition with immune checkpoint inhibitors may improve efficacy in CREPT-driven cancers.
  • Further research into direct CREPT inhibitors is warranted for clinical application.
Keywords:
CREPTcancercell cyclecyclin D1therapeutic target

More Related Videos

Impedance-based Real-time Measurement of Cancer Cell Migration and Invasion09:23

Impedance-based Real-time Measurement of Cancer Cell Migration and Invasion

Published on: April 2, 2020

6.5K
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.7K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.9K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
36.0K